Astellas Sued Over Efforts To Block Generic Prograf

Law360, New York (March 01, 2011, 11:44 PM ET) -- The owners of a retail drug chain filed an antitrust class action Tuesday accusing Astellas Pharma US Inc. of abusing the U.S. Food and Drug Administration’s drug approval process to delay a generic version of Prograf and corner the market for the immunosuppressant.

Stephen L. LaFrance Holdings Inc. filed a complaint in the U.S. District Court for the District of Massachusetts claiming Astellas violated the Sherman Act by illegally maintaining a monopoly in the market for Prograf and charging supracompetitive prices for the drug.

The Pine...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Stephen L. LaFrance Holdings, Inc. et al v. Astellas Pharma US, Inc.


Case Number

1:11-cv-10344

Court

Massachusetts

Nature of Suit

Anti-Trust

Judge

Rya W. Zobel

Date Filed

February 28, 2011

Law Firms

Companies

Government Agencies